Clinical Trials Browser

Phase 3 × Has results × Carcinoma, Transitional Cell × Clear all

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase 3 Completed

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

Phase 3 Terminated

282 enrolled 29 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase 3 Completed

506 enrolled 13 charts

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT02450331 2023-06-18

IMvigor010

Phase 3 Terminated

809 enrolled 19 charts

Carcinoma, Transitional Cell

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

71 enrolled 16 charts 2 FDA

Carcinoma, Carcinoma, Transitional Cell

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Phase 3 Terminated

1 enrolled 5 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms